Auxilius’ Post

Unlocking Efficiency: How Dry Chemistry Analyzers Are Transforming Labs According to the assessment study by Growth Plus Reports, the global dry chemistry analyzer market was valued at 𝐔𝐒$ 𝟏𝟐.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟏 and is expected to register a revenue 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟒.𝟐𝟖% to reach 𝐔𝐒$ 𝟏𝟕.𝟕 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎. A Dry Chemistry Analyzer is a medical device used in clinical laboratories and healthcare settings to analyze various substances and components in biological samples like blood, serum, plasma, urine, or other bodily fluids without the need for liquid reagents or wet chemistry processes. Get free sample PDF now: https://lnkd.in/gBSKV_mC Top companies:              Sysmex Corporation Snibe Teco Diagnostics Erba Mannheim F. Hoffmann-La Roche Ltd Ortho Clinical Diagnostics Hitachi Danaher Corporation Siemens #ChemistryAnalyzer #ClinicalDiagnosis #LabTech #MedicalDevices #HealthcareTech #DiagnosticTools #LaboratoryEquipment #PointOfCareTesting #BiomedicalTechnology #AnalyticalChemistry #Biotechnology #InnovationInHealthcare #MedicalInstruments #Diagnostics #PatientCare #HealthTech #BiomedicalScience #LabAutomation

Budget impact analysis (BIA) is a pharmacoeconomic analysis tool that can help you assess the expected changes in the health expenditure, affordability of new product acquisition, and assess the financial consequences of recommending a novel intervention. Try this model template for calculations. (from the national Centre for pharmaco-economics).. https://lnkd.in/dA3whC7p #hta #healtheconomics #healthcaremanagement #healthcarebusiness

I've recently read an article that shed light on the fascinating landscape of the Global Scientific Instruments Market up to 2030. 🔬 Scientific instruments, often overlooked, are truly the underpinning of innovative leaps. Delving into the numbers, the market had a valuation of $41B in 2022 and is anticipated to touch a whopping USD $58B billion by 2030. Several factors are impacting this positive trend. - Enhanced promotional activities, - Strengthened government-industry ties, - A surge in R&D, - Growth in biotech and pharma sectors, - Potential for new products and forensic tool applications. On the flip side, navigating the tightrope of regulatory compliance, especially in crucial sectors, and meeting the stringent monitoring standards set by regulatory authorities are challenges that the industry must face head-on. Having absorbed these insights, I'm keen to hear your thoughts. How do you foresee the evolution of this industry in the next 7 years?

Revolutionizing Healthcare: The Future of Blood Gas & Electrolyte Analysis According to the assessment study by Growth Plus Reports, the global blood gas & electrolyte analyzer market was valued at 𝐔𝐒$ 𝟏.𝟕𝟖 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐 and is expected to register a revenue 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟒.𝟕𝟖% to reach 𝐔𝐒$ 𝟐.𝟕𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟏. A blood gas and electrolyte analyzer is a medical device used to measure various parameters in a blood sample that provide important insights into a person's acid-base balance, respiratory function, and electrolyte levels. Get free sample PDF now: https://lnkd.in/dpSht3R8 Top companies:            Abbott F. Hoffmann-La Roche Ltd Medica Corporation Siemens Healthcare Pvt. Ltd. EDAN Instruments, Inc. Radiometer OPTI MEDICAL SYSTEMS GMBH Alere Inc. ADVANZ PHARMA #MedicalTechnology #HealthcareInnovation #LabEquipment #CriticalCare #DiagnosticTools #ClinicalTesting #PointOfCare #PatientMonitoring #PrecisionMedicine #HealthTech #LabAnalysis #BloodGasAnalysis #ElectrolyteBalance #MedicalDevices #RespiratoryHealth #AcidBaseBalance #ElectrolyteDisorders #HealthcareSolutions #PatientCare #HealthcareIndustry

Session 10 | Probability of Success: From Medicines to Energy Different Industries - Similar Issues Estimating the probability of success to guide investment decisions spans multiple industries and technologies. This is true whether a company is contemplating investing in developing new molecular treatments for unmet medical needs or investing in assets to meet a future demand for energy. This session presents example methods in use today and compares/contrasts these approaches during Q&A with the audience. The presenters illustrate how combining classical decision analysis, probability elicitation, and advances in predictive modeling can provide plausible estimates of success to guide decision making. #SDG

Session 10 | Probability of Success: From Medicines to Energy Different Industries - Similar Issues Estimating the probability of success to guide investment decisions spans multiple industries and technologies. This is true whether a company is contemplating investing in developing new molecular treatments for unmet medical needs or investing in assets to meet a future demand for energy. This session presents example methods in use today and compares/contrasts these approaches during Q&A with the audience. The presenters illustrate how combining classical decision analysis, probability elicitation, and advances in predictive modeling can provide plausible estimates of success to guide decision making. #SDG

Session 10 | Probability of Success: From Medicines to Energy Different Industries - Similar Issues Estimating the probability of success to guide investment decisions spans multiple industries and technologies. This is true whether a company is contemplating investing in developing new molecular treatments for unmet medical needs or investing in assets to meet a future demand for energy. This session presents example methods in use today and compares/contrasts these approaches during Q&A with the audience. The presenters illustrate how combining classical decision analysis, probability elicitation, and advances in predictive modeling can provide plausible estimates of success to guide decision making. #SDG

Session 10 | Probability of Success: From Medicines to Energy Different Industries - Similar Issues Estimating the probability of success to guide investment decisions spans multiple industries and technologies. This is true whether a company is contemplating investing in developing new molecular treatments for unmet medical needs or investing in assets to meet a future demand for energy. This session presents example methods in use today and compares/contrasts these approaches during Q&A with the audience. The presenters illustrate how combining classical decision analysis, probability elicitation, and advances in predictive modeling can provide plausible estimates of success to guide decision making. #SDG

Session 10 | Probability of Success: From Medicines to Energy Different Industries - Similar Issues Estimating the probability of success to guide investment decisions spans multiple industries and technologies. This is true whether a company is contemplating investing in developing new molecular treatments for unmet medical needs or investing in assets to meet a future demand for energy. This session presents example methods in use today and compares/contrasts these approaches during Q&A with the audience. The presenters illustrate how combining classical decision analysis, probability elicitation, and advances in predictive modeling can provide plausible estimates of success to guide decision making. #SDG

【Future of life sciences】 Expectations of life sciences companies today include faster innovation, transparent drug pricing, and a greater purpose beyond profits. Some companies are hunkering down to weather the current economic storm. However, leaders are rethinking their operating models to ensure they can meet stakeholder expectations, anticipate threats, and capitalize on data-driven insights to win in the marketplace. In this paper, KPMG professionals examine four primary signals of change and four strategic imperatives that represent the future of life sciences. https://lnkd.in/gDBHTdbb